Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: A feasibility study

Neuro-Oncology

Volumn 14, Issue 1, 2012, Pages 79-86

  Balducci, Mario ^a   Chiesa, Silvia ^a   Diletto, Barbara ^a   D'Agostino, Giuseppe Roberto ^a   Mangiola, Annunziato ^a   Manfrida, Stefania ^a   Mantini, Giovanna ^a   Albanese, Alessio ^a   Fiorentino, Alba ^a   Frascino, Vincenzo ^a   De Bari, Berardino ^a   Micciche', Francesco ^a   De Rose, Fiorenza ^a   Morganti, Alessio Giuseppe ^a   Anile, Carmelo ^a   Valentini, Vincenzo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Glioblastoma; Hyper radiosensitivity; Low dose fractionated radiotherapy; Palliative treatment; Radiochemotherapy

Indexed keywords

CISPLATIN; FOTEMUSTINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; RETREATMENT; SKIN MANIFESTATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PALLIATIVE CARE; PROGNOSIS;

EID: 84856244319     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor173     Document Type: Article

References (70)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society, 2008.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
3. Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):690-691.
4. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms: An update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-180. (Pubitemid 43261763)
5. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trial. J Clin Oncol. 1999;17:2572-2578. (Pubitemid 29368260)
6. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CC1-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J Clin Oncol. 2005;23:5294-5304. (Pubitemid 46206983)
7. Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol. 2011;98(1):1-14.
8. Taghian A, Ramsay J, Allalunis-Turner J, et al. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1993;25(2):243-249. (Pubitemid 23048776)
9. Johannessen TC, Bjerkvig R, Tysnes BB. DNA repair and cancer stemlike cells-potential partners in glioma drug resistance? Cancer Treat Rev. 2008;34(6):558-567.
10. Lowe SW, Ruley HE, Jacks T, Housman DE, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967. (Pubitemid 23289454)
11. Benjamin B, David C, Dieter L, et al. Defective p53antiangiogenic signaling in glioblastoma. Neuro-Oncol. 2010;12(9):894-907.
12. Chendil D, Oakes R, Alcock RA, et al. Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer. 2000;89:1893-1900.
13. Ella LK, Robin W, Anne R. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-Oncol. 2010;12(4):389-400.
14. Chen P, Iavarone A, Fick J, et al. Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet. 1995;82:106-115.
15. Wu JK, Ye Z, Darras BT, et al. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurg. 1993;33:824-830.
16. Van Meir EG, Polverini PJ, Chazin VR, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 1994;54:649-652. (Pubitemid 24068319)
17. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 1992;355:846-847.
18. Frankel RH, Bayona W, Koslow M, Newcomb EW. P53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency. Cancer Res. 1992;52:1427-1433.
19. D'Avenia P, Porrello A, Berardo M, et al. p53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: A strategy to convert a radio-resistant phenotype into a radiosensitive one. Cancer Lett. 2006;231:102-112. (Pubitemid 41779458)
20. Short SC, Mitchell SA, Boulton P, Woodcock M, Joiner MC. The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol. 1999;75:1341-1348.
21. Short S, Mayes C, Woodcock M, Johns H, Joiner MC. Low-dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol. 1999;75:847-855. (Pubitemid 29336561)
22. Beauchesne PD, Bertrand S, Branche R, et al. Human malignant glioma cell lines are sensitive to low radiation doses. Int J Cancer. 2003;105:33-40. (Pubitemid 36418482)
23. Krause M, Wohlfarth J, Georgi B, et al. Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol. 2005;81(10):751-758. (Pubitemid 43200510)
24. Lambin P, Malaise EP, Joiner MC. The effect of very low radiation doses on the human bludder cell line RT112. Radiother Oncol. 1994;32:63-72. (Pubitemid 24246765)
25. Lambin P, Marples B, Fertil B, Malaise EP, Joiner MC. Hypersensitivity of a human tumour cell line to very low radiation doses. Int J Radiat Biol. 1993;63:639-650. (Pubitemid 23162770)
26. Joiner MC. Induced radioresistance: An overview and historical perspective. Int J Radiat Biol. 1994;65:79-84. (Pubitemid 24063533)
27. Singh B, Arrand JE, Joiner MC. Hypersensitive response of normal human lung epithelial cells at low radiation doses. Int J Radiat Biol. 1994;65:457-464. (Pubitemid 24162503)
28. Wouters BG, Skarsgard LD. The response of a human tumor cell line to low radiation doses: Evidence of enhanced sensitivity. Radiat Res. 1994;138:S76-S80. (Pubitemid 24116648)
29. Wouters BG, Sy AM, Skarsgard LD. Low dose hypersensitivity and increased radioresistance in a panel of human tumor cell lines with different radiosensitivity. Radiat Res. 1996;146:399-413. (Pubitemid 26332772)
30. Marples B, Lambin P, Skov KA, Joiner MC. Low dose hyperradiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol. 1997;71:721-735. (Pubitemid 27306027)
31. Short SC, Kelly J, Mayes CR, Woodcock M, Joiner MC. Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol. 2001;77:655-664. (Pubitemid 32531882)
32. Dey S, Spring PM, Arnold S, et al. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res. 2003;9: 1557-1565. (Pubitemid 36418414)
33. Gupta S, Arnold AM, Spring P, et al. Low-dose fractionated radiation potentiates the effect of cisplatin independent of the hyper-radiation sensitivity phenomenon in human lung cancer cell lines [Abstract]. Proc Am Assoc Cancer Res. 2004;45:1369a.
34. Arnold SM, Regine WF, Ahmed MM, et al. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: Results of a new treatment paradigm. Int J Radiat Oncol Biol Phys. 2004;58:1411-1417. (Pubitemid 38438301)
35. Spring PM, Arnold SM, Shajahan S, et al. Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle. 2004;3: 479-485. (Pubitemid 40278242)
36. Garofalo MC, Bacler-Kubiczek EK, Ahmed MM, et al. Chemopotentiation with low-dose fractionated radiation therapy: A promising novel treatment paradigm. Lancet Oncol. In press.
37. Regine WF, Hanna N, Garofalo MC, et al. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: A phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys. 2007;68(1):172-177. (Pubitemid 46589824)
38. Simpson L, Galanis E. Recurrent glioblastoma multiforme: Advances in treatment and promising drug candidates. Expert Rev Anticancer Ther. 2006;6(11):1593-1607. (Pubitemid 44883962)
39. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22(23):4779-4786.
40. Franceschi E, Omuro AM, Lassman AB, et al. Salvage temozolomide for prior temozolomide responders. Cancer. 2005;104(11):2473-2476. (Pubitemid 41691570)
41. Meulemans A, Giroux B, Hannoun P, Robine D, Henzel D. Comparative diffusion study of two nitrosoureas: Carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy. 1991;37:86-92.
42. Fischel JL, Formento P, Etienne MC, Gioanni J, et al. In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol. 1990;25:337-341. (Pubitemid 20048640)
43. De Wit MC, de Bruin HG, EijkenboomW, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63(3):535-537. (Pubitemid 39031388)
44. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
45. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S20-S27.
46. Rodier JM, Da Costa L, Adams D, et al. Fotemustine and cisplatin association in patients with recurrent malignant glioma [Abstract]. Proc Am Sol Clin. 1996;292.
47. Phillips C, Guiney M, Smith JA. Randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol. 2003;68(1):23-26. (Pubitemid 37289332)
48. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v4.0; ctep.cancer.gov/reporting/ctc.html
49. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280. (Pubitemid 20195640)
50. Joiner MC, Denekamp J, Maughan RL. The use of "top-up" experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;49:565-580. (Pubitemid 16105455)
51. Deutsch M, Green SB, Strike TA, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys. 1989;16:1389-1396. (Pubitemid 19154320)
52. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer. 1996;15:1535-1543.
53. Brada M, Baumert B. Focal fractionated conformal stereotactic boost following conventional radiotherapy of high-grade gliomas: A randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10). Front Radiat Ther Oncol. 1999;33:241-243.
54. Joiner MC, Johns H. Renal damage in the mouse: The response to very small doses per fraction. Radiation Research. 1988;114:385-398.
55. Turesson I, Nyman J, Qvarnström F, et al. A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis. Radiother Oncol. 2010;94(1):90-101.
56. Rachidi W, Harfourche G, Lemaitre G, Amiot F, Vaigot P, Martin MT. Sensing radiosensitivity of human epidermal stem cells. Radiother Oncol. 2007;83(3):267-276. (Pubitemid 46915550)
57. Gay H. Role of the linear-quadratic model in high doses per fraction. Radiother Oncol. 2010;94(1):122-123.
58. Courdi A. High doses per fraction and the linear-quadratic model. Radiother Oncol. 2010;94(1):121-122.
59. Short SC,Woodcock M, Marples B, Joiner MC, et al. Effects of cell cycle phase on low-dose hyper-radiosensitivity. Int J Radiat Biol. 2003;79(2):99-105. (Pubitemid 36183068)
60. Lambin P, Malaise EP, Joiner MC. Might intrinsic radioresistance of human tumor cells be induced by radiation. Int J Radiat Biol. 1996;69:279-290. (Pubitemid 26153270)
61. Joiner MC, Marples B, Lambin P, Short SC, Turesson I, et al. Low-dose hypersensitivity: Current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 2001;49:37989.
62. Marples B, Wouters BG, Collis SJ, Chalmers AJ, Joiner MC, et al. Low-dose hyper-radiosensitivity: A consequence of ineffective cell cycle arrest of radiationdamaged G2-phase cells. Radiat Res. 2004;161:247-255. (Pubitemid 40797066)
63. Enns L, Bogen KT, Wizniak J, Murtha AD, Weinfeld M, et al. Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res. 2004;2(10):557-566. (Pubitemid 39403384)
64. Short SC, Woodcock M, Marples B, Joiner MC. Effects of cell cycle phase on low-dose hyper-radiosensitivity. Int J Radiat Biol. 2003;79(2):99-105. (Pubitemid 36183068)
65. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide vs radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
66. Beauchesne P, Bernier V, Carnin C, et al. Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro-Oncol. 2010;12(6): 595-602.
67. Valentini V, Massaccesi M, Balducci M, et al. Low-dose hyperradiosensitivity: Is there a place for future investigation in clinical settings? Int J Radiat Oncol Biol Phys. 2010;76(2):535-539.
68. Franceschi E, Tosoni A, Bartolini S, Mazzocchi V, Fioravanti A, Brandes AA. Treatment options for recurrent glioblastoma: Pitfalls and future trends. Expert Rev Anticancer Ther. 2009;9(5):613-619.
69. Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances. Crit Rev Oncol Hematol. 2006;60(3):181-193. (Pubitemid 44709618)
70. Wick A, Pascher C, Wick W, et al. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol. 2009;256(5): 734-741.